In vivo analysis reveals a novel bispecific antibody's antitumor potential in RPMI8226 xenograft models, indicating improved efficacy with minimal cytokine release.
In vivo comparison of FIT-Ig candidates with different CD3 affinities in RPMI8226 xenograft model. A, Antitumor activity of vehicle; CD3hi FIT-Ig; and CD3 med FIT-Ig in human PBMC and RPMI8226 cell line derived xenograft M-NSG mice. Two injections of test articles were performed once a week. B, Body weight changes were measured twice a week after dosing.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: